J A Pineda

Summary

Country: Spain

Publications

  1. doi request reprint Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain
    Nicolas Merchante
    Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Avenida de Bellavista S N, Sevilla 41014, Spain
    Clin Infect Dis 56:143-50. 2013
  2. doi request reprint Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis
    Juan A Pineda
    Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avenida de Bellavista S N, 41014 Seville, Spain
    J Infect 64:204-11. 2012
  3. doi request reprint Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Sevilla, Spain
    HIV Clin Trials 9:309-13. 2008
  4. pmc HAART and the liver: friend or foe?
    J A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Sevilla, Spain
    Eur J Med Res 15:93-6. 2010
  5. doi request reprint Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis
    J A Pineda
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Seville, Spain
    J Antimicrob Chemother 61:925-32. 2008
  6. doi request reprint Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    Clin Infect Dis 51:788-95. 2010
  7. doi request reprint Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients
    Juan A Pineda
    Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain
    AIDS 25:1415-20. 2011
  8. ncbi request reprint Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy
    Juan A Pineda
    Unidad Clínica de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    Hepatology 46:622-30. 2007
  9. doi request reprint Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    J Acquir Immune Defic Syndr 51:445-9. 2009
  10. doi request reprint Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients
    J A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    J Viral Hepat 17:714-9. 2010

Detail Information

Publications78

  1. doi request reprint Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain
    Nicolas Merchante
    Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Avenida de Bellavista S N, Sevilla 41014, Spain
    Clin Infect Dis 56:143-50. 2013
    ..To report the clinical and epidemiological characteristics of hepatocellular carcinoma (HCC) diagnosed in a cohort of human immunodeficiency virus (HIV)-infected patients in Spain...
  2. doi request reprint Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis
    Juan A Pineda
    Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avenida de Bellavista S N, 41014 Seville, Spain
    J Infect 64:204-11. 2012
    ..To assess the frequency of severe liver toxicity in HIV/hepatitis C (HCV)-coinfected patients with advanced liver fibrosis receiving efavirenz (EFV)-based antiretroviral combinations...
  3. doi request reprint Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Sevilla, Spain
    HIV Clin Trials 9:309-13. 2008
    ..To appraise the incidence of liver toxicity in a population of patients receiving fosamprenavir/ritonavir (FPV/r) with a high frequency of viral hepatitis co-infection...
  4. pmc HAART and the liver: friend or foe?
    J A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Sevilla, Spain
    Eur J Med Res 15:93-6. 2010
    ..As well, an improvement of the clinical outcome of liver disease has been reported in patients taking HAART. For these reasons, the short- and mid-term effects of HAART on the liver are mostly beneficial...
  5. doi request reprint Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis
    J A Pineda
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Seville, Spain
    J Antimicrob Chemother 61:925-32. 2008
    ..Moreover, the relationship between these events and the degree of prior liver fibrosis was evaluated...
  6. doi request reprint Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    Clin Infect Dis 51:788-95. 2010
    ..We aimed to assess the predictive ability of variations in the single-nucleotide polymorphism rs12979860 for SVR in HIV/HCV-coinfected patients, regardless of HCV genotype...
  7. doi request reprint Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients
    Juan A Pineda
    Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain
    AIDS 25:1415-20. 2011
    ....
  8. ncbi request reprint Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy
    Juan A Pineda
    Unidad Clínica de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    Hepatology 46:622-30. 2007
    ..15 (2.45-106.48)], a diagnosis of cirrhosis at recruitment [13.69 (5.55-34.48)], hepatic encephalopathy [62.5 (21.27-200)] and lower CD4 cell gain [3.63 (1.45-9.09)] were associated with mortality due to liver failure...
  9. doi request reprint Liver stiffness as a predictor of esophageal varices requiring therapy in HIV/hepatitis C virus-coinfected patients with cirrhosis
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    J Acquir Immune Defic Syndr 51:445-9. 2009
    ..The aim of this study was to assess the ability of LS to predict esophageal varices requiring preventive therapy for bleeding in HIV/HCV-coinfected patients...
  10. doi request reprint Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients
    J A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    J Viral Hepat 17:714-9. 2010
    ..Older age, alcohol consumption and lower CD4 cell counts are related with significant fibrosis. The latter association supports an earlier starting of antiretroviral therapy in this setting...
  11. ncbi request reprint Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients
    Juan A Pineda
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Spain
    J Antimicrob Chemother 60:1347-54. 2007
    ....
  12. doi request reprint Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients
    Juan A Pineda
    Unit of Infectious Diseases, Hospital Universitario de Valme, Hospital Universitario Virgen del Rocio, Seville, Spain
    Clin Infect Dis 49:1274-82. 2009
    ..To provide information about the incidence and predictors of liver decompensation and death due to liver failure in human immunodeficiency virus (HIV)-infected patients with compensated hepatitis C virus (HCV)-related cirrhosis...
  13. doi request reprint Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients
    N Merchante
    Unidad de Enfermedades Infecciosas Hospital Universitario de Valme Avenida de Bellavista, Sevilla, Spain
    Gut 58:1654-60. 2009
    ..It is not known if insulin resistance (IR), a condition that promotes liver fibrosis in HCV mono-infected individuals, is one of these factors...
  14. doi request reprint Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice
    J Macias
    Hospital Universitario de Valme, Seville, Spain
    HIV Med 11:439-47. 2010
    ..We therefore examined the value of the APRI and FI in HIV/HCV-coinfected patients for the detection of significant fibrosis in real-life conditions...
  15. ncbi request reprint Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus
    J Macias
    Servicio de Medicina Interna, Hospital Universitario de Valme, Carretera de Cádiz s n, 41014 Seville, Spain
    Eur J Clin Microbiol Infect Dis 22:675-80. 2003
    ..The mean increase in CD4+ cell counts was lower in the HCV-positive group during the first year of therapy. HIV/HCV-coinfected patients naïve for antiretroviral therapy show a delayed recovery of CD4+ cell counts after starting HAART...
  16. pmc Prevalence of and factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain
    J A Pineda
    Viral Hepatitis and AIDS Study Group, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain
    J Clin Microbiol 36:2419-22. 1998
    ..There is also an association of this disease with male sex and intravenous drug use...
  17. ncbi request reprint Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients
    N Merchante
    Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    J Viral Hepat 13:449-56. 2006
    ..01-39.36). There was no association between HOMA-IR values and the presence of advanced fibrosis or a faster fibrosis progression. Thus IR is not associated with liver damage or fibrosis progression in HIV/HCV-coinfected individuals...
  18. ncbi request reprint HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination
    J Macias
    Servicio de Medicina Interna, Hospital Universitario Virgen de Valme, Seville, Spain
    Eur J Clin Microbiol Infect Dis 20:46-8. 2001
    ..Therefore, influenza immunization of patients with undetectable viremia achieved with highly active antiretroviral therapy does not seem to affect VL...
  19. ncbi request reprint Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain
    A Sanchez-Quijano
    Viral Hepatitis and AIDS Study Group, Department of Internal Medicine, Virgen del Rocio University Hospital, Seville, Spain
    J Hepatol 27:25-9. 1997
    ..The aim of the present study was to investigate the epidemiological, clinical and molecular characteristics of these patients...
  20. doi request reprint Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV
    A Rivero-Juárez
    Unidad de Enfermedades Infecciosas, Instituto Maimonides de Investigacion Biomedica de Cordoba IMIBIC, Hospital Universitario Reina Sofia, Cordoba, Spain
    Infection 41:21-6. 2013
    ..The aim of the study was to identify baseline risk factors for VR in HIV/HCV co-infected patients treated with pegylated interferon plus ribavirin (PEG-INF/RBV)...
  21. ncbi request reprint Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy
    J M Franco
    Department of Internal Medicine, Virgen del Rocio University Hospital, Seville, Spain
    Eur J Clin Microbiol Infect Dis 18:733-6. 1999
    ..In summary, this study shows that highly active antiretroviral therapy is able to induce a strong deactivation of the immune system of HIV-1-infected patients...
  22. doi request reprint Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus
    Juan Macias
    Infectious Diseases Unit, Hospital Universitario de Valme, Seville, Spain
    Hepatology 50:1056-63. 2009
    ..61 [0.39-0.93], P = 0.03), moderate-to-severe lobular necroinflammation (1.77 [1.16-2.7], P = 0.009), time between biopsies (1.11 [1.08-1.2], P = 0.01), and end of treatment response to anti-HCV therapy (0.41 [0.19-0.88], P = 0.02)...
  23. ncbi request reprint Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients
    J Fernández-Rivera
    Servicio de Medicina Interna, Hospital Universitario de Valme, Seville, Spain
    HIV Clin Trials 4:337-46. 2003
    ....
  24. ncbi request reprint Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection
    F A Di Lello
    Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avenida de Bellavista S N, 41014, Seville, Spain
    Eur J Clin Microbiol Infect Dis 32:1427-35. 2013
    ..This complementary effect of both genotypes is also observed on the plasma levels of low-density lipoprotein cholesterol (LDL-C)...
  25. pmc Low sensitivity of peripheral blood smear for diagnosis of subclinical visceral leishmaniasis in human immunodeficiency virus type 1-infected patients
    J Delgado
    Viral Hepatitis and AIDS Study Group, Virgen del Rocio University Hospital, Seville, Spain
    J Clin Microbiol 36:315-6. 1998
    ..In this study, Leishmania amastigotes were seen in blood smears from 1 of 13 HIV-1-positive individuals with subclinical VL. This shows that this procedure is not suitable for subclinical-VL diagnosis...
  26. ncbi request reprint Minimal liver injury in chronic hepatitis C virus infection is associated with low levels of soluble TNF-alpha/Fas receptors and acquisition in childhood
    J Macias
    Servicio de Medicina Interna, Hospital Universitario Virgen de Valme, Seville, Spain
    Liver 21:410-4. 2001
    ..The rate of progression to cirrhosis of chronic hepatitis C might be related to an upregulation of TNF-alpha/Fas pathways...
  27. doi request reprint Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment
    K Neukam
    Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avda de Bellavista, 41014, Sevilla, Spain
    Eur J Clin Microbiol Infect Dis 31:1225-32. 2012
    ..The efficacy of HCV therapy in MMT patients is similar to that found in subjects not taking methadone. MMT patients should be equally considered for treatment with pegylated interferon plus ribavirin in HCV-infected patients...
  28. ncbi request reprint Structural normalization of the lymphoid tissue in asymptomatic HIV-infected patients after 48 weeks of potent antiretroviral therapy
    J Macias
    Servicio de Medicina Interna, Hospital Universitario Virgen de Valme, ctra Cadiz s n, 41014 Seville, Spain
    AIDS 15:2371-8. 2001
    ..The hallmark of HIV infection is the involution and destruction of lymphoid tissue. However, very little information exists on the effect of highly active antiretroviral therapy (HAART) on lymphoid tissue structure...
  29. doi request reprint Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients
    José del Valle
    Infectious Diseases Unit, Hospital Universitario de Valme, Sevilla, Spain
    AIDS 22:923-30. 2008
    ..There are no data concerning this topic in HIV/hepatitis C virus coinfected patients in whom lipid disorders are particularly common...
  30. doi request reprint Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients
    Nicolas Merchante
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    J Hepatol 50:684-92. 2009
    ..To evaluate the possible influence of baseline insulin resistance in sustained virological response...
  31. ncbi request reprint Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy
    J Macias
    Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Avda Bellavista s n, 41014, Seville, Spain
    Eur J Clin Microbiol Infect Dis 31:2083-8. 2012
    ..As TGF-beta1 levels have been shown to increase over time in HCV infection and liver fibrosis worsens rapidly in HIV/HCV coinfection, these parameters seem to evolve in a different way in MVC-treated patients...
  32. ncbi request reprint Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy
    E Ramayo
    Unidad de Enfermedades Infecciosas, Servicio de Analisis Clinicos, Hospital Universitario de Valme, 41014 Seville, Spain
    AIDS Res Hum Retroviruses 21:915-21. 2005
    ..However, antiretroviral drug-naive patients showed lower serum levels of vitamin D metabolites and free testosterone than HAART-treated patients...
  33. ncbi request reprint Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum beta2microglobulin levels
    J A García-García
    Departamento de Medicina Interna, Hospital Universitario de Valme, Carretera de Cádiz s n, 41014, Sevilla, Spain
    Eur J Clin Microbiol Infect Dis 22:194-6. 2003
    ..These results show that HCV infection precludes immune deactivation in HIV-infected patients undergoing highly active antiretroviral therapy...
  34. ncbi request reprint Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients
    Jose A Mira
    Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 12:523-9. 2007
    ..Our objective was to determine if rapid virological response (RVR) at week 4 of therapy with peg-IFN and RBV could predict SVR among HIV/HCV-coinfected patients...
  35. ncbi request reprint Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients
    Jose A Mira
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 12:1225-35. 2007
    ..The objective of this study was to identify predictors of severe haematological toxicity among HIV-HCV-coinfected patients treated with PEG-IFN plus RBV...
  36. doi request reprint Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone
    Jose A Mira
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Spain
    J Antimicrob Chemother 62:1365-73. 2008
    ....
  37. ncbi request reprint Low levels of HIV-1 plasma viral load in patients infected with HIV-1 subtype b and advanced immunosuppression
    R De la Rosa
    Department of Internal Medicine, Virgen del Rocio University Hospital, Seville, Spain
    J Infect 42:4-7. 2001
    ..Likewise, a PCR procedure adapted for detecting HIV-1 non-B subtypes fails to find higher plasma viraemia in patients with such a discordance...
  38. ncbi request reprint [Prevalence of serum antibodies against Bartonella ssp. in a health population from the south area of the Seville province]
    J A García-García
    Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla
    Rev Clin Esp 205:541-4. 2005
    ..To know the prevalence of serum antibodies against Bartonella spp. in a healthy population from south of Spain...
  39. ncbi request reprint Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy
    J Macias
    Servicio de Medicina Interna, Hospital Universitario de Valme, Ctra Cádiz, S N, 41014 Seville, Spain
    Eur J Clin Microbiol Infect Dis 21:775-81. 2002
    ..8). Although liver failure is an increasing cause of death among HIV-infected patients receiving HAART, HCV infection has still no impact on the survival of HIV-infected patients...
  40. ncbi request reprint Evidence of increased risk for leishmania infantum infection among HIV-seronegative intravenous drug users from southern Spain
    J A Pineda
    Servicio de Medicina Interna, Hospital Universitario Virgen de Valme, Seville, Spain
    Eur J Clin Microbiol Infect Dis 20:354-7. 2001
    ..33; 95% confidence interval, 1.03-5.24). The prevalence of Leishmania infection markers among intravenous drug users is higher than that among controls. This suggests that this parasite spreads through the sharing of needles...
  41. ncbi request reprint Usefulness of route of transmission, absolute CD8+ T-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1-infected patients with very low CD4 + T-cell counts
    J Macias
    Servicio de Medicina Interna, Hospital Universitario Virgen de Valme, Seville, Spain
    Eur J Clin Microbiol Infect Dis 20:253-9. 2001
    ....
  42. doi request reprint Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients
    J Macias
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Seville, Spain
    HIV Med 12:14-21. 2011
    ....
  43. pmc Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes
    J Macias
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Ctra de Cadiz s n, 41014 Seville, Spain
    Gut 55:409-14. 2006
    ....
  44. ncbi request reprint Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C
    Juan Macias
    Hospital Universitario de Valme, Seville, Spain
    Antivir Ther 11:839-46. 2006
    ..The use of PI-based HAART in HIV/HCV-coinfected patients is associated with less severe fibrosis and slower progression of fibrosis. The nucleoside analogue backbone in a HAART regimen may influence this association...
  45. ncbi request reprint Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease
    Nicolas Merchante
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    AIDS 20:49-57. 2006
    ..To find the survival and the predictors of death of HIV-infected patients with hepatitis C virus (HCV)-related end-stage liver disease (ESLD)...
  46. ncbi request reprint A review of current anti-HCV treatment regimens and possible future strategies
    Karin Neukam
    Hospital Universitario de Valme, Unidad Clínica de Enfermedades Infecciosas, 41014 Seville, Spain
    Expert Opin Pharmacother 10:417-33. 2009
    ..Hepatitis C virus (HCV) infection remains a serious health problem worldwide. The current standard treatment of HCV infection is pegylated interferon-alpha plus ribavirin, but this is clearly not sufficiently effective and tolerable...
  47. doi request reprint Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression
    Jose A Mira
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Hospital Universitario Virgen del Rocio, Sevilla, Spain
    Clin Infect Dis 49:e84-91. 2009
    ..SVR rates among patients with a CD4 cell count <or=250 cells/mm(3) at baseline were compared with those among patients with CD4 cell counts >250 cells/mm(3). The association between SVR and potential predictors was analyzed...
  48. ncbi request reprint Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine
    Juan Macias
    Servicio de Medicina Interna, Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Seville, Spain
    AIDS 18:767-74. 2004
    ..The data on the effect of protease inhibitors (PI) on liver fibrosis are scant and contradictory. No information is available on the relationship between non-nucleoside analogue therapy and liver fibrosis in co-infected patients...
  49. ncbi request reprint The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection
    Salvador Vergara
    Clinical Unit of Infectious Diseases, Department of Internal Medicine, Hospital Universitario de Valme, Seville, Spain
    Clin Infect Dis 45:969-74. 2007
    ..The purpose of this study was to validate reported cutoff values of TE that discriminate significant liver fibrosis and cirrhosis in HIV-HCV-coinfected subjects...
  50. doi request reprint Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients
    Juan Macias
    Clinical Unit of Infectious Diseases, Department of Internal Medicine, Seville, Spain
    J Hepatol 49:916-22. 2008
    ..Because of this, we elaborated and validated cut-off values of liver stiffness (LS) to better discriminate F < or = 1 from F > or = 2 in HIV/HCV co-infected subjects to aid therapy decisions...
  51. ncbi request reprint Bilateral enophthalmos as a manifestation of HIV infection-related lipoatrophy
    N Merchante
    Department of Internal Medicine, University Hospital de Valme, Carretera de Cádiz, s n 41014, Seville, Spain
    HIV Med 5:448-9. 2004
  52. ncbi request reprint Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy
    Rosario Palacios
    Unidad de Enfermedades Infecciosas, Hosp Virgen de la Victoria, Malaga, Spain
    Antivir Ther 11:529-35. 2006
    ..to assess the incidence and risk factors for insulin resistance (IR) in a cohort of naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy (HAART)...
  53. ncbi request reprint Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients
    Salvador Vergara
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Seville, Spain
    J Antimicrob Chemother 59:87-91. 2007
    ..To assess the association between non-severe liver enzyme elevations (LEEs) during antiretroviral treatment and liver fibrosis in HIV/HCV-coinfected patients...
  54. ncbi request reprint Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis
    José A García-García
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    AIDS Res Hum Retroviruses 22:1236-41. 2006
    ..This is probably due to the fact that HIV infection shortens the survival of HCV-coinfected patients with end-stage liver disease to such an extent that HCC not had a chance to emerge...
  55. doi request reprint Impact of observer experience on the reproducibility of transient elastometry in HIV/HCV co-infected patients
    Karin Neukam
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    HIV Clin Trials 10:276-81. 2009
    ..Data on the influence of observer experience on transient elastometry (TE) in hepatitis C virus (HCV) infection are scarce, and there are no data on HCV/HIV co-infected patients...
  56. ncbi request reprint Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy
    Juan A Pineda
    Service of Internal Medicine, Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    J Antimicrob Chemother 55:417-9. 2005
    ..Additionally, in coinfected patients, other factors that promote fibrogenesis, such as alcohol consumption, should be avoided. Antiviral treatment of chronic hepatitis C could also reduce the risk of liver damage associated with HAART...
  57. doi request reprint Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis
    Jose R Arribas
    Servicio de Medicina Interna, Hospital La Paz, Universidad Autonoma de Madrid, Madrid, Spain
    J Acquir Immune Defic Syndr 51:147-52. 2009
    ..However, it is still uncertain if this experimental strategy can maintain suppression in the long term...
  58. doi request reprint Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine
    Nicolas Merchante
    Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 15:753-63. 2010
    ..Our objective was to search for the presence of abnormal liver stiffness (LS) in a cohort of HIV-infected patients without HBV or HCV coinfection and to assess the related factors...
  59. doi request reprint Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis
    Juan Macias
    Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Seville, Spain
    J Antimicrob Chemother 63:178-83. 2009
    ..The aim of this study was to evaluate the incidence and risk factors of severe liver events among HIV-infected patients treated with drug combinations including tipranavir boosted with ritonavir (TPV/r)...
  60. doi request reprint High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack
    Juan Macias
    Servicio de Medicina Interna, Hospital Universitario de Valme, Seville, Spain
    Liver Int 28:781-6. 2008
    ..Because of this, we evaluated the prevalence of and factors associated with HCV infection among NIDU...
  61. ncbi request reprint Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment
    Jose A Mira
    Servicio de Medicina Interna, Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 9:511-7. 2004
    ..However, there are insufficient data on the relationship between gynaecomastia and any specific antiretroviral drug and hormone abnormality...
  62. ncbi request reprint HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis
    Juan A Pineda
    Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario de Valme, 41014 Sevilla, Spain
    Hepatology 41:779-89. 2005
    ..This fact must be taken into account to establish the adequate timing of liver transplantation in HIV-coinfected subjects...
  63. ncbi request reprint Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure
    Jose A Mira
    Servicio de Medicina Interna, Hospital Universitario de Valme, Seville, Spain
    Antivir Ther 7:251-6. 2002
    ..To analyse whether blips are associated with a higher risk of virological or immunological failure than persistent undetectable viraemia (UND) among HIV-infected patients receiving HAART...
  64. ncbi request reprint Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C
    Jose A Mira
    Servicio de Medicina Interna, Hospital Universitario de Valme Sevilla, Spain
    J Antimicrob Chemother 58:140-6. 2006
    ..To determine the incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among human immunodeficiency virus/hepatitis C virus (HIV/HCV)-coinfected patients with known stage of liver fibrosis...
  65. ncbi request reprint Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy
    Juan Macias
    Servicio de Medicina Interna, Hospital Universitario de Valme, Seville, Spain
    J Infect 51:195-200. 2005
    ..We assessed the emergence of new drug resistance mutations during blips among HIV-infected patients on HAART from a cohort in which we found no association between blips and virological failure...
  66. ncbi request reprint Management of HCV-related end-stage liver disease in HIV-coinfected patients
    Nicolas Merchante
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    AIDS Rev 9:131-9. 2007
    ..Liver transplantation seems to be a proper option of treatment in HIV/HCV-coinfected patients and should be considered early in their management, since mortality after the first hepatic decompensation is high...
  67. ncbi request reprint Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection
    Juan Macias
    Servicio de Medicina Interna, Hospital Universitario de Valme, Seville, Spain
    J Infect Dis 192:1566-76. 2005
    ..We sought to compare the expression of Fas on hepatocytes and irreversible apoptosis of hepatocytes among patients with CHC with and without HCV/HIV coinfection...
  68. pmc Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients
    José A García-García
    Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario de Valme, Carretera de Cádiz s n, 41014 Seville, Spain
    J Clin Microbiol 44:4455-8. 2006
    ..Conversely, Leishmania antigen in urine was not detected in these patients...
  69. ncbi request reprint Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry
    Karin Neukam
    Unit of Infectious Diseases, Hospital Universitario de Valme, Seville, Spain
    Eur J Gastroenterol Hepatol 22:801-7. 2010
    ..This study was aimed to determine the interobserver concordance of TE measurements in HIV/HCV-coinfected patients...
  70. pmc Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy
    Rafael de la Rosa
    Viral Hepatitis and AIDS Study Group, Servicio de Medicina Interna, Hospital Universitario Virgen del Rocío Servicio de Medicina Interna, Hospital Universitario de Valme, Seville, Spain
    J Clin Microbiol 40:762-7. 2002
    ..In summary, the use of HAART has led to a fall in the incidence of symptomatic VL in HIV-infected patients. The main risk factor associated with kala-azar emergence in patients infected with HIV is deep immunosuppression...
  71. ncbi request reprint Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy
    Jose A Mira
    Servicio de Medicina Interna e Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Seville, Spain
    Am J Trop Med Hyg 70:298-301. 2004
    ..047). The frequency of VL relapses in patients receiving HAART is high. Relapses of VL are observed only in individuals with uncontrolled HIV replication and/or poor immunologic responses...
  72. doi request reprint [Non alcoholic steatosis in HIV infection]
    Nicolas Merchante
    Servicio de Medicina Interna, Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Espana
    Med Clin (Barc) 133:112-6. 2009
    ..There is no specific therapy for NASH in HIV infection, as the role of glitazones has not been evaluated in these patients...
  73. doi request reprint Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen
    Manuel Crespo
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    J Antimicrob Chemother 62:793-6. 2008
    ..However, data available on the efficacy of this therapy in co-infected patients who failed a former interferon-based regimen are limited...
  74. ncbi request reprint Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
    ..There is little information about the influence of antiretroviral drugs on the antiviral activity of pegylated interferon (PEG-IFN) plus ribavirin (RBV) against hepatitis C virus (HCV)...
  75. ncbi request reprint Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C
    Juan Macias
    Hepatology 42:498; author reply 498-9. 2005
  76. ncbi request reprint Prevalence of non-significant liver fibrosis and rate of fibrosis progression in HIV/hepatitis C virus- co-infected patients: still a role for liver biopsy?
    Nicolas Merchante
    AIDS 18:1746-8. 2004
  77. ncbi request reprint Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir
    Juan A Pineda
    J Antimicrob Chemother 57:1016-7. 2006
  78. ncbi request reprint Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors
    Antonio Rivero
    Seccion de Enfermedades Infecciosas, Hospital Universitario Reina Sofia, Cordoba, Spain
    J Antimicrob Chemother 59:342-6. 2007
    ..In any case, it is unusual for an NNRTI to be suspended due to liver toxicity...